OncoMatch/Clinical Trials/NCT04314219
Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients
Is NCT04314219 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Cyclophosphamide 50mg and Methotrexate for acute lymphoblastic leukemia (all) in complete remission.
Treatment: Cyclophosphamide 50mg · Methotrexate — This randomized clinical trial will evaluate two approaches of GvHD prophylaxis; the standard of care GVHD prophylaxis regimen (methotrexate/calcineurin inhibitors) and post-transplant cyclophosphamide with calcineurin inhibitors for their efficacy as a new GVHD prophylaxis strategy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Disease stage
Required: Stage COMPLETE REMISSION
Excluded: Stage ACTIVE DISEASE
Demographics
Lab requirements
Kidney function
estimated creatinine clearance greater than 50 ml/minute
Liver function
total bilirubin < 2x the upper limit of normal (unless elevated bilirubin is attributed to gilbert's syndrome) and alt/ast < 2.5x the upper normal limit
Cardiac function
ejection fraction at rest ≥ 50% by muga or tte
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04314219 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage COMPLETE REMISSION is required.
Is there an age limit?
Yes. Patients must be 65 years or younger and at least 14 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify